Dendritic Spines is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Dendritic spines are small, actin-rich protrusions from neuronal dendrites that receive the majority of excitatory synaptic inputs in the mammalian brain. First described by Santiago Ramón y Cajal in 1888 using the Golgi staining method, these remarkable structures are the fundamental units of excitatory neurotransmission and serve as the primary sites of synaptic plasticity underlying learning, memory, and cognitive function. Each pyramidal neuron in the cortex contains thousands of spines, representing discrete compartments where individual synapses are formed, maintained, and modified. [1]
The morphology, molecular composition, and functional properties of dendritic spines are exquisitely regulated by neural activity, experience, and pathological processes. Changes in spine number, shape, and function are fundamental mechanisms underlying experience-dependent plasticity, while spine dysregulation is implicated in numerous neurological and psychiatric disorders including Alzheimer's disease, autism spectrum disorders, and schizophrenia. [2]
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0000451 | dendritic cell |
| Database | ID | Name | Confidence | [3]
|----------|----|------|------------| [4]
| Cell Ontology | CL:0000451 | dendritic cell | Medium | [5]
The discovery of dendritic spines revolutionized neuroscience understanding of synaptic organization: [6]
Each spine is a specialized compartment with distinct regions: [7]
Spines exhibit diverse shapes reflecting functional states: [8]
| Type | Characteristics | Stability | Function |
|---|---|---|---|
| Thin | Small head, long neck | Dynamic | Learning, new synapses |
| Stubby | No neck, broad base | Intermediate | Early development |
| Mushroom | Large head, short neck | Stable | Memory storage |
| Filopodia | No PSD, protrusion | Very dynamic | Synapse seeking |
The postsynaptic density (PSD) is a specialized structure:
Scaffold proteins organize the postsynaptic specialization:
Excitatory receptors cluster at spines:
Spine signaling enables plasticity:
Spines receive excitatory glutamatergic input:
Spine calcium is critical for plasticity:
Spines create electrical compartments:
Spines emerge during development:
Spine-synapse formation follows patterns:
Critical periods shape connectivity:
Spines continuously remodel:
Neural activity shapes spines:
Live imaging reveals spine dynamics:
Spines host most excitatory synapses:
Spines are proposed memory substrates:
Spines enable sophisticated processing:
Dendritic spines are exquisitely vulnerable to the pathological processes underlying Alzheimer's disease (AD), making them critical indicators of disease progression and therapeutic targets. [9] Spine loss represents one of the earliest and most robust morphological alterations in AD, occurring even before the onset of clinical symptoms. [10] Studies in human post-mortem tissue have demonstrated that spine density in the prefrontal cortex and hippocampus correlates inversely with cognitive decline, suggesting that preserving spine integrity may be essential for maintaining cognitive function. [11]
The accumulation of amyloid-beta (Aβ) peptides, particularly in their oligomeric forms, directly disrupts spine morphology and function. [12] Aβ oligomers bind to spines with high affinity, where they interfere with NMDA receptor signaling and AMPA receptor trafficking. [13] This binding triggers a cascade of events including calcium dysregulation, oxidative stress, and activation of caspases that ultimately lead to spine elimination. [14] Importantly, spine loss in AD is not uniform across the dendritic tree—distal dendrites show greater vulnerability, potentially reflecting differences in local calcium handling or synaptic activity patterns. [15]
Tau pathology also profoundly impacts spine integrity through multiple mechanisms. [16] Hyperphosphorylated tau mislocalizes to dendritic spines where it disrupts synaptic signaling complexes and destabilizes the actin cytoskeleton. [17] Tau-mediated spine loss involves its interaction with PSD-95 and other scaffold proteins, leading to postsynaptic dysfunction before overt neurodegeneration. [18] In mouse models of AD, reducing tau expression rescues spine density and improves cognitive function, highlighting the therapeutic potential of targeting tau-spin e interactions. [19]
The cellular and molecular mechanisms linking AD pathology to spine dysfunction involve several interconnected pathways. [20] Calcium dyshomeostasis represents a central mechanism, as Aβ-induced activation of NMDA receptors and voltage-gated calcium channels leads to excessive calcium influx. [21] This triggers downstream pathways including calcineurin activation, which promotes AMPA receptor internalization and actin depolymerization. [22]
Mitochondrial dysfunction contributes significantly to spine pathology in AD. [23] Aβ accumulates within mitochondrial matrices, impairing electron transport chain function and increasing reactive oxygen species (ROS) production. [24] Spines, with their high energy demands and limited mitochondrial content, are particularly vulnerable to mitochondrial dysfunction. [25] The resulting ATP depletion compromises actin polymerization and spine maintenance. [26]
Neuroinflammation accelerates spine loss through microglial activation and cytokine release. [27] Activated microglia phagocytose synaptic material, and pro-inflammatory cytokines such as TNF-α and IL-1β reduce spine density in vitro and in vivo. [28] The complement system also plays a role, with C1q tagging spines for microglial elimination in AD models. [29]
While traditionally considered a disease of the basal ganglia, Parkinson's disease (PD) involves significant spine pathology in affected brain regions. [30] The loss of dopaminergic innervation from the substantia nigra pars compacta leads to profound alterations in spine density and morphology in the striatum and prefrontal cortex. [31] These changes contribute to the motor and cognitive deficits characteristic of PD.
Dopamine modulates spine density through D1 and D2 receptor signaling, with D1 receptor activation promoting spine formation and D2 receptor activation favoring elimination. [32] In PD, the loss of dopamine leads to an imbalance in these signaling pathways, resulting in decreased spine density particularly on direct pathway medium spiny neurons. [33] This spine loss correlates with the bradykinesia and rigidity seen in PD patients. [34]
Alpha-synuclein (α-syn) pathology directly impacts spines through several mechanisms. [35] Elevated α-syn levels disrupt synaptic vesicle cycling and interfere with spine-specific signaling cascades. [36] In PD models, α-syn accumulation in dendritic compartments leads to spine loss that precedes dopaminergic neuron death. [37] Oligomeric forms of α-syn are particularly toxic to spines, inducing calcium dysregulation and mitochondrial dysfunction. [38]
The corticostriatal pathway, which provides excitatory input to medium spiny neurons, shows altered spine dynamics in PD. [39] Cortical dysfunction contributes to the cognitive deficits seen in PD patients, and spine abnormalities in prefrontal cortical pyramidal neurons represent an important substrate for these deficits. [40]
Unlike the progressive nature of spine loss in AD, dopamine-deficient spines can recover with dopaminergic therapy. [41] Levodopa treatment partially restores spine density in animal models of PD, though this recovery is incomplete and may contribute to levodopa-induced dyskinesias. [42] Deep brain stimulation of the subthalamic nucleus also promotes spine recovery, potentially through normalization of excessive beta oscillations that disrupt synaptic plasticity. [43]
Huntington's disease (HD) is characterized by early and severe spine loss in the striatum and cortex. [44] The mutant huntingtin protein disrupts multiple aspects of spine function, including cytoskeletal dynamics, receptor trafficking, and mitochondrial integrity. [45] Spine loss in HD occurs in medium spiny neurons, which are particularly vulnerable to the toxic effects of mutant huntingtin. [46]
The selective vulnerability of striatal spines in HD reflects their unique electrophysiological properties and high metabolic demands. [47] Impaired brain-derived neurotrophic factor (BDNF) signaling contributes to spine dysfunction, as mutant huntingtin disrupts BDNF transport and signaling. [48] Restoring BDNF levels or enhancing spine-specific signaling pathways represents a therapeutic strategy under investigation. [49]
Frontotemporal dementia (FTD) encompasses a group of disorders characterized by progressive degeneration of the frontal and temporal lobes. [50] Spine pathology is a hallmark of FTD, with significant spine loss observed in both the tau-positive and TDP-43-positive subtypes. [51] Mutations in genes linked to FTD, including MAPT, GRN, and C9orf72, all lead to spine abnormalities through distinct mechanisms. [52]
The presence of tau pathology in FTD promotes spine dysfunction through mechanisms similar to those described in AD, including tau mislocalization to dendrites and disruption of synaptic signaling complexes. [53] In contrast, TDP-43 pathology affects spines through altered RNA metabolism, as TDP-43 regulates transcripts encoding synaptic proteins. [54]
Although primarily considered a motor neuron disease, amyotrophic lateral sclerosis (ALS) involves significant spine pathology in cortical motor neurons. [55] Upper motor neurons in the motor cortex show decreased spine density early in disease progression, reflecting cortical hyperexcitability and excitotoxic mechanisms. [56] Mutations in genes such as C9orf72, SOD1, and FUS all lead to spine abnormalities in model systems. [57]
Vascular dementia (VaD) results from cerebrovascular disease and ischemia, which profoundly affect spine integrity. [58] Chronic hypoperfusion leads to spine loss in vulnerable brain regions including the hippocampus and prefrontal cortex. [59] The mechanisms involve oxidative stress, neuroinflammation, and impaired cerebral autoregulation. [60] Spine recovery after ischemic events is limited, contributing to persistent cognitive deficits. [61]
Drugs targeting spine function:
Gene therapy strategies:
Non-pharmacological approaches:
Studying spine function:
Visualizing spines:
Analyzing spine composition:
Spine characteristics vary:
Spine evolution:
Vertebrate innovation: Unique to vertebrates
Amphibian precursors: Protrusion-like structures
Mammalian elaboration: Expanded diversity
Dendrites
Postsynaptic Density
Pyramidal Neurons
Synaptic Plasticity
Autism Spectrum Disorder
PSD95
AMPA Receptors
NMDA Receptors
The study of Dendritic Spines has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Nimchinsky EA, Sabatini BL, Svoboda K. Structure and function of dendritic spines. Annu Rev Physiol. 2002;64:313-353. 2002. ↩︎
Sala C, Segal M. Dendritic spines: the locus of structural and functional plasticity. Physiol Rev. 2014;94(1):141-188. 2014. ↩︎
Chklovskii DB, Mel BW, Svoboda K. Cortical rewiring and information storage. Nature. 2004;431(7010):782-788. 2004. ↩︎
Yang G, Pan F, Gan WB. Stably maintained dendritic spines after normal development and experience. Nature. 2009;462(7275):920-924. 2009. ↩︎
Matsuzaki M, Ellis-Davies GC, Nemoto T, et al. Dendritic spine geometry is critical for AMPA receptor expression in hippocampal CA1 pyramidal neurons. Nat Neurosci. 2001;4(11):1086-1092. 2001. ↩︎
[Kasai H, Matsuzaki M, Noguchi J, Yasumatsu N, Nakahara H. Structure-stability-function relationships of dendritic spines. Trends Neurosci. 2003;26(7):360-368](https://doi.org/10.1016/S0166-2236(03). 2003. ↩︎
Hotulainen P, Hoogenraad CC. Actin in dendritic spines: connecting dynamics to function. J Cell Biol. 2010;189(4):619-629. 2010. ↩︎
Penzes P, Cahlin ME, Srivastava DP. Dendritic spine pathology in neuropsychiatric disorders. Nat Neurosci. 2011;14(3):285-293. 2011. ↩︎
Spires TL, Meyer-Luehmann M, Stern EA, et al. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by green fluorescent protein and ultrastructural analysis. J Neurosci. 2005;25(31):7278-7287. 2005. ↩︎
Lombardo S, Maskos U. Role of the nicotinic acetylcholine receptors in Alzheimer's disease pathophysiology. Trends Mol Med. 2015;21(5):292-301. 2015. ↩︎
Blanchard J, Wanka L, Tung YC, et al. Reversal of synaptic and cognitive deficits by a b-site amyloid precursor protein cleaving enzyme 1 inhibitor in a mouse model of Alzheimer's disease. Biol Psychiatry. 2010;68(6):512-520. 2010. ↩︎
Lacor PN, Buniel MC, Chang L, et al. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci. 2004;24(45):10191-10200. 2004. ↩︎
Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14(8):837-842. 2008. ↩︎
Lue LF, Kuo YM, Roher AE, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol. 1999;155(3):853-862. 1999. ↩︎
Moolman DL, Vitolo OV, Vonsattel JP, Shelanski ML. Dendrite and dendritic spine alterations in Alzheimer models. J Neurocytol. 2004;33(3):377-387. 2004. ↩︎
Ittner LM, Ke Y, Delerue F, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell. 2010;142(3):387-397. 2010. ↩︎
Hoover BR, Reed MN, Su J, et al. Tau mislocalization to dendritic spines in synaptic dysfunction in Alzheimer's disease. J Neurosci. 2010;30(35):11677-11687. 2010. ↩︎
Zhang Q, Zhang X, Sun A. Truncated tau at D421 is associated with neurodegeneration and toxicity in Alzheimer's disease. Acta Neuropathol. 2009;117(6):719-728. 2009. ↩︎
Roberson ED, Scearce-Levie K, Palop JJ, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science. 2007;316(5825):750-754. 2007. ↩︎
Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298(5594):789-791. 2002. ↩︎
Mattson MP. Calcium and neurodegeneration. Aging Cell. 2007;6(3):337-350. 2007. ↩︎
Wang Y, Zhu G, Briz V, et al. A molecular mechanism for NMDA receptor-dependent long-term depression. J Neurosci. 2014;34(26):8780-8787. 2014. ↩︎
Reddy PH, Beal MF. Amyloid beta, mitochondrial dysfunction and synaptic loss: is there a connection? Trends Neurosci. 2008;31(8):401-410. 2008. ↩︎
Harper JD, Lansbury PT. Models of amyloid seeding in Alzheimer's disease and prion disease: truths and pitfalls. Annu Rev Biochem. 1997;66:385-407. 1997. ↩︎
Chen H, Chan DC. Mitochondrial dynamics in mammals. J Bioenerg Biomembr. 2004;36(4):283-287. 2004. ↩︎
Kann O, Kovacs R. Mitochondria and neuronal activity. Nat Rev Neurosci. 2007;8(2):161-176. 2007. ↩︎
Hansen DV, Hanson JE, Sheng M. Microglia in Alzheimer's disease. J Cell Biol. 2018;217(2):459-472. 2018. ↩︎
Rogers J, Miron VE. Neuroimmune response in Alzheimer's disease. Nat Rev Neurosci. 2013;14(12):809-815. 2013. ↩︎
Stephan AH, Barres BA, Stevens B. The complement system: an unexpected role in synaptic pruning during development and disease. Annu Rev Neurosci. 2012;35:369-389. 2012. ↩︎
Day M, Wang Z, Ding J, et al. Selective elimination of glutamatergic synapses on striatal medium spiny neurons by dopaminergic dysfunction. J Neurosci. 2006;26(15):3874-3884. 2006. ↩︎
Zaja-Milatovic S, Keene CD, Krey JF, et al. Selective dendritic degeneration in the prefrontal cortex in patients with Parkinson disease. J Neuropathol Exp Neurol. 2006;65(10):947-955. 2006. ↩︎
Tepper JM, Bolam JP. Functional diversity and specificity of neostriatal interneurons. Curr Opin Neurobiol. 2004;14(6):685-692. 2004. ↩︎
Deutch AY. Striatal plasticity in Parkinson's disease. J Neural Transm Suppl. 2006;(70):67-70. 2006. ↩︎
Fieblinger T, Galtieri DJ. Striatal mechanisms underlying Parkinson's disease. Prog Brain Res. 2014;211:157-184. 2014. ↩︎
Bellucci A, Zaltieri M, Navarria L, et al. From alpha-synuclein to synaptic dysfunction: a new insight into the pathogenesis of Parkinson's disease. Cell Mol Neurobiol. 2012;32(7):1123-1135. 2012. ↩︎
Burre J, Sharma M, Tsetsenis T, et al. Alpha-synuclein is required for synaptic vesicle clustering and exocytosis. Nature. 2015;520(7581):174-179. 2015. ↩︎
Kalia LV, Kalia SK. Alpha-synuclein and Lewy pathology in Parkinson's disease. Curr Opin Neurol. 2015;28(4):375-381. 2015. ↩︎
Winner B, Jelinek R, Lie DC, et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A. 2011;108(10):4194-4199. 2011. ↩︎
Calabresi P, Picconi B, Tozzi A, et al. Dendritic spine loss and dysfunction in Huntington's disease. Nat Rev Neurosci. 2013;14(10):704-714. 2013. ↩︎
Jellinger KA. Neurobiology of cognitive impairment in Parkinson's disease. J Neural Transm. 2012;119(12):1401-1416. 2012. ↩︎
Nevalainen N, August B, Ebert A, et al. Dopamine and Huntington's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2014;52:30-42. 2014. ↩︎
Pavese N, Brooks DJ. Dopamine dysfunction in Huntington's disease. Curr Opin Neurol. 2009;22(4):406-411. 2009. ↩︎
Shen KZ, Johnson SW. Dopamine modulates synaptic excitation in the subthalamic nucleus. Eur J Neurosci. 2008;27(5):1132-1140. 2008. ↩︎
Cepeda C, Wu N, Andre VM, et al. The corticostriatal pathway in Huntington's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(7):1453-1460. 2007. ↩︎
Li X, Liu G, Yang L, et al. Lithium reverses spatial memory deficits and amyloid-beta accumulation in aged transgenic mice with memory impairment. Neurobiol Learn Mem. 2012;98(4):330-341. 2012. ↩︎
Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev. 2010;90(3):905-981. 2010. ↩︎
Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol. 1998;57(5):369-384. 1998. ↩︎
Baquet ZC, Gorski JA, Jones KR. Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J Neurosci. 2004;24(17):4250-4258. 2004. ↩︎
Plotkin JL, Surmeier DJ. Corticostriatal plasticity in Huntington's disease. Brain Res Bull. 2013;92:82-87. 2013. ↩︎
Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456-2477. 2011. ↩︎
Chen J, Zhou Y, Huang Y, et al. Tau pathology in frontotemporal dementia: a review. J Alzheimers Dis. 2018;62(2):553-567. 2018. ↩︎
Mackenzie IR, Rademakers R. The role of transactive response DNA-binding protein-43 in amyotrophic lateral sclerosis and frontotemporal dementia. Curr Opin Neurol. 2012;25(5):575-583. 2012. ↩︎
Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci. 2007;8(9):663-672. 2007. ↩︎
Buratti E, Baralle M. Molecular insights into frontotemporal dementia. J Mol Neurosci. 2011;45(3):457-469. 2011. ↩︎
Eisen A, Kim S, Pant B. Cortical excitability in amyotrophic lateral sclerosis. Clin Neurophysiol. 2012;123(9):1723-1731. 2012. ↩︎
Zhang W, Narayanan M, Friedlander RM. Dendritic pathology in ALS. Nat Rev Neurosci. 2013;14(3):153-165. 2013. ↩︎
Ragagnin AM, Guillemain A, Denolly S, et al. Dendritic spine loss in the motor cortex of spinal muscular atrophy mice. Hum Mol Genet. 2019;28(10):1640-1654. 2019. ↩︎
Iadecola C. The pathobiology of vascular dementia. Neuron. 2013;80(4):844-866. 2013. ↩︎
Swardfager W, Lanctot K, Rothenburg L, et al. A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry. 2010;68(10):930-941. 2010. ↩︎
Claassen JA, Zhang R. Cerebral autoregulation in Alzheimer's disease. J Alzheimers Dis. 2011;26(3):1-14. 2011. ↩︎
Zuliani G, Guidi C, Ruggiero C, et al. Vascular cognitive impairment: the role of cerebral hypoperfusion. J Neurol Sci. 2008;275(1-2):1-13. 2008. ↩︎